Archive for April, 2015
(COOL) Executes Definitive Financing Documents, Retires Outstanding Warrants
SOUTH PLAINFIELD, NJ–(Apr 30, 2015) – Majesco Entertainment Company (NASDAQ: COOL) (the “Company’) today announced that on April 29, 2015 it entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors for a financing in the amount of $5,000,000, approximately $1,000,000 of which will be released to the Company on the closing date, and the balance to be held in escrow, expected to occur next week.
Under the terms of the Subscription Agreements, the Company will issue Units at a purchase price of $1.20 per Unit. Each Unit consists of one share of the Company’s Common Stock or, if such issuance of Common Stock would result in the recipient investor exceeding certain threshold ownership restrictions, shares of the Company’s 0% Series C Convertible Preferred Stock (the “Preferred C Shares”), and one three-year Warrant to purchase one share of the Company’s common stock at an initial exercise price of $1.40.
In addition, the Company is completing an exchange of its currently outstanding warrants that were issued to the accredited investors that invested in the Company’s December 17, 2014 private placement. Pursuant to warrant exchange agreements (the “Exchange Agreements”), the Company will retire 8,823,529 warrants exercisable at $0.68 per share in exchange for shares of the Company’s Common Stock or shares of 0% Series B Preferred Convertible Stock (the “Preferred B Shares”), if such issuance would result in the recipient investor exceeding certain thresholds. An aggregate of 6,302,520 shares of Common Stock (which amount includes the shares of Common Stock issuable upon conversion of the Preferred B Shares) are issuable in connection with the Exchange Agreements.
About Majesco Entertainment Company
Majesco Entertainment Company is an innovative developer, marketer, publisher and distributor of interactive entertainment for consumers around the world. Building on more than 25 years of operating history, the company develops and publishes a wide range of video games on console, handheld and mobile platforms, as well as digital networks. Majesco is headquartered in South Plainfield, NJ and the company’s shares are traded on the Nasdaq Stock Market under the symbol: COOL. More info can be found online at majescoent.com or on Twitter at twitter.com/majesco.
Safe Harbor
Some statements set forth in this release contain forward-looking statements that are subject to change. Examples of forward-looking statements include statements relating to industry prospects, our future economic performance including anticipated revenues and expenditures, results of operations or financial position, and other financial items, our business plans and objectives, including our intended product releases, and may include certain assumptions that underlie forward-looking statements. Statements including words such as “anticipate,” “believe,” “estimate” or “expect” and statements in the future tense are forward-looking statements. These statements are subject to business and economic risk and reflect management’s current expectations, and involve subjects that are inherently uncertain and difficult to predict. Some of the risks and uncertainties which could cause our results to differ materially from our expectations include the following: consumer demand for our products, the availability of an adequate supply of current-generation and next-generation gaming hardware; our ability to predict consumer preferences among competing hardware platforms; consumer spending trends; the seasonal and cyclical nature of the interactive game segment; timely development and release of our products; competition in the interactive entertainment industry; developments in the law regarding protection of our products; our ability to secure licenses to valuable entertainment properties on favorable terms; our ability to manage expenses; our ability to attract and retain key personnel; adoption of new accounting regulations and standards; adverse changes in the securities markets; our ability to comply with continued listing requirements of the Nasdaq stock exchange; the availability of and costs associated with sources of liquidity; and other factors described in our filings with the SEC, including our Annual Report on Form 10-K for the year ended October 31, 2014. The Company does not undertake, and specifically disclaims any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
(SYRX) Acquires Assets of LightMiner Systems
Big data software solutions and infrastructure provider Sysorex (NASDAQ: SYRX) today announced it has completed the acquisition of substantially all the assets of LightMiner Systems, including all intellectual property related to its high-speed database management system. Sysorex purchased the big data analytics software platform and the two pending patent applications relating to it for approximately $3.78 million payable in Sysorex common stock to be issued one year from the closing date with the number of shares calculated based on a trailing 20-day volume weighted daily average price with a $2.00 minimum floor. In addition LightMiner Systems founder Chris Baskett will join Sysorex as Vice President of Engineering reporting to Sysorex CTO Craig Harper.
“In today’s highly competitive, data-driven environment, organizations need the ability to manage rapidly growing volumes of information faster and with more flexibility,” said Nadir Ali, CEO of Sysorex. “We believe LightMiner Systems’ unique high speed database technology could enable Sysorex to leap to the forefront of an industry-wide race to manage and analyze massive amounts of data in near-real time on premise or in the cloud.”
The assets acquired from LightMiner Systems include an in-memory, real-time, data analysis system designed to perform very large, highly complex and extremely difficult calculations using off-the-shelf hardware and memory. It supports both traditional SQL-based business intelligence and analytics applications as well as a host of integrated statistical, machine learning and artificial intelligence algorithms allowing it to provide supercomputer-like performance at commodity prices.
“We expect LightMiner’s performance-to-cost ratio will allow Sysorex to take the sort of high end big data analytics that only the largest of enterprises can currently afford, and deliver it to thousands of mid-market and smaller enterprises that haven’t yet been able to take advantage of the big data revolution,” Ali said.
Sysorex expects to begin delivering the LightMiner Systems product both as an on-premise installation and as a service to customers later this year.
About Sysorex
Through focused, custom technology solutions, Sysorex (NASDAQ:SYRX) provides cyber security, data analytics, cloud solutions, Mobile/BYOD solutions and strategic outsourcing to government and commercial clients in major industries around the world. From identifying security risks to helping clients realize value from their big data strategies, Sysorex has the experience, technology, partners, and agility to be your trusted IT partner. Visit www.sysorex.com, follow @SysorexGlobal and Like us on Facebook.
Safe Harbor Statement
All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of the registrant and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.
Sysorex:
A. Sage Osterfeld, 760-707-0459
sage.osterfeld@sysorex.com
or
Sysorex Investor Relations:
CorProminence LLC
Scott Arnold, 516-222-2560
scotta@corprominence.com
www.corprominence.com
(SBSA) Sweepstakes Offers Chance to Win New York Trip, Exclusive Mana Performance
One winner will attend La Musica En Privado concert with Spanish language music legends Mana
CANTON, Mass., April 30, 2015 — America Runs – and rocks – on Dunkin’, as Dunkin’ Donuts announces a special sweepstakes offering the chance to win an all-expense paid trip for two to New York to attend an exclusive performance by Mana, one of the most successful Spanish-language rock bands of all time. Mana’s performance, at the Hammerstein Ballroom in New York City on May 11, is part of the La Musica En Privado concert series, for which Dunkin’ Donuts is the presenting sponsor.
To enter the sweepstakes, fans can visit http://lamusicaenprivado.com now to May 1. The grand prize includes airfare for the winner and a guest, hotel and transportation accommodations. No purchase necessary, must be 21+ to enter. Void where prohibited.
Dunkin’ Donuts has partnered with AIRE Radio Networks, a division of Spanish Broadcasting System (Nasdaq: SBSA) to present La Musica En Privado, a unique concert series featuring captivating performances from some of the world’s most renowned Latino music stars in private and intimate settings. The series includes four exclusive concerts throughout 2015, featuring some of today’s most popular Spanish language artists. The first La Musica En Privado concert was held in March in Miami, headlined by Luis Fonsi and Jencarlos Canela. Fans across the world can enjoy the shows across the AIRE Radio Network, online and via the AIRE La Musica mobile app.
Additionally, Dunkin’ Donuts is partnering with Universal Music and Juan Luis Guerra to license Ojala Que Lluva Cafe. This song will be integrated into a Dunkin’ Donuts radio commercial that will run on the SBS/AIRE Radio Networks, supporting the music program and Dunkin’ Donuts’ coffee leadership.
“We are proud to partner with AIRE Radio Networks and Spanish Broadcasting System to present La Musica En Privado. The first event in this series was a great success, and we are thrilled to offer our sweepstakes to give one lucky fan a special chance to attend the next concert with Spanish language music legends Mana,” said Xavier Turpin, Director of Multicultural Marketing for Dunkin’ Donuts. “As we continue to increase our focus on serving and marketing to the growing and important Hispanic community, this partnership is a wonderful example of our commitment to develop fun and unique ways to celebrate our fans and thank them for their loyalty.”
To learn more about Dunkin’ Donuts, visit www.DunkinDonuts.com or follow us on Facebook (www.facebook.com/DunkinDonuts) and Twitter (www.twitter.com/DunkinDonuts).
About Dunkin’ Donuts
Founded in 1950, Dunkin’ Donuts is America’s favorite all-day, everyday stop for coffee and baked goods. Dunkin’ Donuts is a market leader in the hot regular/decaf/flavored coffee, iced coffee, donut, bagel and muffin categories. Dunkin’ Donuts has earned the No. 1 ranking for customer loyalty in the coffee category by Brand Keys for nine years running. The company has more than 11,300 restaurants in 36 countries worldwide. Based in Canton, Mass., Dunkin’ Donuts is part of the Dunkin’ Brands Group, Inc. (Nasdaq: DNKN) family of companies. For more information, visit www.DunkinDonuts.com.
Contact:
Heather McIntyre
Dunkin’ Brands
781-737-5200
Heather.McIntyre@dunkinbrands.com
(BLVDU) To Acquire AgroFresh Business From The Dow Chemical Company
NEW YORK, April 30, 2015 — Boulevard Acquisition Corp. (NASDAQ: BLVD, BLVDU, BLVDW), an entity sponsored by an affiliate of Avenue Capital Group, announced today that it has entered into a definitive agreement with The Dow Chemical Company (NYSE: DOW) under which Boulevard will acquire AgroFresh, Dow’s post-harvest specialty chemical business, in a transaction that will result in AgroFresh becoming a publicly traded company with an anticipated initial enterprise value of $879 million, or 8.7x its estimated 2015 EBITDA.
AgroFresh is a global industry leader in providing innovative data-driven specialty chemical solutions aimed at enabling growers and packers of fresh produce to preserve and enhance the freshness, quality and value of fresh produce and to maximize the percentage of produce supplied to the market relative to the amount of produce grown. Its flagship product is the SmartFreshSM Quality System, a freshness protection technology proven to maintain firmness, texture and appearance of fruits during storage and transport. SmartFresh™ is currently commercialized in 45 countries worldwide.
Marc Lasry, Chairman of Boulevard Acquisition Corp., said, “We are pleased to work with Dow and the AgroFresh management team to introduce the company to the public markets. After reviewing a significant number of potential acquisitions, we believe that AgroFresh is well positioned to generate strong risk-adjusted returns for our shareholders. It is the leading post-harvest specialty chemical business, with multiple paths for continued profitable growth ahead of it.”
Upon completion of the transaction, AgroFresh will become a stand-alone public company listed on NASDAQ. Dow will retain a non-consolidated minority ownership position in the company, and will be represented on the Board of AgroFresh. It is intended that Thomas Macphee, currently vice president and corporate director for Dow, who had formally been responsible for AgroFresh in the company’s early development, will be named Chief Executive Officer of AgroFresh upon completion of the transaction. “I am excited by the opportunity to lead this impressive global specialty chemicals business,” Mr. Macphee added.
Stephen Trevor, President and Chief Executive Officer of Boulevard Acquisition Corp., said, “AgroFresh is the leading agricultural solutions provider in a strong macro environment driven by global food demand growth. We look forward to partnering with the AgroFresh team as it benefits from these dynamics and continues to execute its growth strategy.”
Key Transaction Terms
Under the terms of the definitive agreements for the transaction, at closing, Boulevard will purchase AgroFresh in exchange for 18.4 million shares of Boulevard Common Stock and $626 million in cash, for a total of $810 million assuming a valuation of the Boulevard shares at $10 per share.
Dow will initially hold approximately 40% of the shares of AgroFresh while the stockholders of Boulevard will initially hold approximately 60%.
The transaction has been unanimously approved by the Boards of Directors of Boulevard and Dow, and is expected to close in the third quarter of 2015. Closing is subject to approval by Boulevard’s shareholders, the completion of customary regulatory filings, and other customary closing conditions.
A full description of the transaction terms will be provided in the proxy statement that Boulevard intends to file with the Securities and Exchange Commission (“SEC”) to be used at its special meeting of stockholders in lieu of an annual meeting to approve the proposed transaction with Dow. Stockholders are advised to read, when available, Boulevard’s preliminary proxy statement and definitive proxy statement in connection with the solicitation of proxies for the special meeting because these statements will contain important information. The definitive proxy statement will be mailed to stockholders as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain a copy of the proxy statement, without charge, by directing a request to: Boulevard Acquisition Corp., 399 Park Avenue, 6th Floor, New York, NY 10022. The preliminary proxy statement and definitive proxy statement, once available, can also be obtained, without charge, at the SEC’s internet site (http://www.sec.gov).
Investor Conference Call Scheduled
Boulevard will host an investor conference call to discuss the transaction on Thursday, April 30, 2015 at 11:00a.m. EDT. Investors may listen to the conference call by dialing (855) 327-6837 toll free in the U.S. or (778) 327-3988 internationally. The presentation slides and a replay of the call will be available at the following web address beginning April 30 at 12:00p.m. EDT until 12:00p.m. on May 7, 2015: https://viavid.webcasts.com/starthere.jsp?ei=1063040
About Boulevard Acquisition Corp.
Boulevard Acquisition Corp. is a public investment vehicle formed by Avenue Capital Group for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Boulevard completed its initial public offering in February 2014, raising $220.5 million in cash proceeds.
Boulevard’s officers and certain of its directors are affiliated with Avenue Capital Group. Avenue is an established global alternative investment firm founded in 1995. Avenue’s primary focus is investing in credit and other special situation investments in the United States, Europe and Asia. Avenue has approximately $13.0 billion in assets under management as of March 31, 2015. Additional information about Boulevard is available at www.boulevardacq.com.
Forward-Looking Statements
This news release may include “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this news release that address activities, events or developments that Boulevard expects or anticipates will or may occur in the future are forward-looking statements and are identified with, but not limited to, words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. These statements are based on certain assumptions and analyses made by Boulevard in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances. Actual results may differ materially from those expressed herein due to many factors such as, but not limited to, the ability to satisfy closing conditions for the transaction, including stockholder and other approvals, the performances of Boulevard and AgroFresh, the ability of the combined company to meet the Nasdaq Capital Market’s listing standards, including having the requisite number of stockholders, and the risks identified in Boulevard’s prior and future filings with the SEC (available at www.sec.gov), including the proxy statement to be filed in connection with the proposed transaction and Boulevard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. These statements speak only as of the date they are made and Boulevard undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances which arise after the date of this news release. Investors are cautioned that forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of AgroFresh, Boulevard and the combined group after completion of the proposed business combination are based on current expectations that are subject to risks and uncertainties.
Participants in the Business Combination
Boulevard and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Boulevard in connection with the transaction. Information regarding the officers and directors of Boulevard is available in Boulevard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which has been filed with the Securities and Exchange Commission. Additional information regarding the interests of such potential participants will also be included in the definitive proxy statement and other relevant documents filed or to be filed by Boulevard with the Securities and Exchange Commission regarding the transaction.
Disclaimer
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Contacts
For Boulevard Acquisition Corp.
Todd Fogarty
Kekst and Company
+1 (212) 521-4854
todd-fogarty@kekst.com
Neil Shah
Citigroup Global Markets Inc.
+1 (212) 723-3264
neil.shah@citi.com
(CKSW) to Go Private; Definitive Agreement to Be Acquired by Francisco Partners
Transaction Valued at approximately $438 Million; ClickSoftware Shareholders to Receive $12.65 per Share in All Cash Transaction
BURLINGTON, Mass., April 30, 2015 — ClickSoftware Technologies Ltd. (NasdaqGS: CKSW) (the “Company”), the leading provider of automated mobile workforce management and optimization solutions for the service industry, today announced that it has signed a definitive agreement to be acquired by private funds managed by Francisco Partners Management L.P. (“FP” or “Francisco Partners”), a leading global technology-focused private equity firm, in an all-cash transaction valued at approximately $438 million.
Under the terms of the agreement, Francisco Partners will acquire all of ClickSoftware’s outstanding ordinary shares for $12.65 per share in cash. This represents a premium of approximately 45% over the average closing price of the Company’s shares on the Nasdaq Global Select Market during the previous 90 calendar days. The Board of Directors of ClickSoftware unanimously approved the merger agreement and recommends that ClickSoftware’s shareholders approve the agreement.
Dr. Moshe BenBassat, Founder and CEO of ClickSoftware, said, “After a comprehensive evaluation and review of strategic alternatives designed to enhance shareholder value, we are confident this agreement represents a favorable outcome for our shareholders, providing them with immediate, substantial cash value. Furthermore, we are excited to partner with Francisco Partners, a firm with an established track record of working with companies transitioning to Cloud and with companies in relevant verticals to ClickSoftware. The added flexibility we will have as a private company, combined with the benefit of FP’s knowledge and domain expertise, will allow us to more effectively focus on our long-term investment and growth objectives, which will benefit our employees, customers and partners.”
“We are excited to support the continued growth of ClickSoftware,” said Matt Spetzler, Partner at Francisco Partners. “ClickSoftware is a leader in the mobile workforce management space, and we look forward to combining our expertise with its talented team of professionals to further enhance its Cloud solutions, grow its customer pipeline and further advance its strategic goals.”
The transaction is subject to certain closing conditions, including approval of the Company’s shareholders. The transaction is not contingent upon receiving third party financing. ClickSoftware’s shareholders will be asked to vote on the proposed transaction at a special meeting of shareholders that will be held on a date to be announced. ClickSoftware expects the transaction to be completed in July 2015. Upon completion, ClickSoftware will become a privately held company.
Jefferies LLC is acting as exclusive financial advisor to ClickSoftware. Amit, Pollak, Matalon & Co. is acting as legal counsel to ClickSoftware, and Sullivan & Worcester LLP is acting as U.S. counsel to ClickSoftware.
Barclays Capital Inc. is acting as exclusive financial advisor and Meitar Liquornik Geva Leshem Tal is serving as legal counsel to Francisco Partners.
Preliminary First Quarter Results
ClickSoftware today also announced preliminary results for the first quarter ended March 31, 2015. Revenue for the first quarter of 2015 is expected to be in the range of $26 to $27 million. The Company expects to incur a net operating loss on a GAAP and non-GAAP basis for the first quarter of 2015.
The above information is preliminary and subject to ClickSoftware’s normal quarter-end accounting process and review, and after which full results will be available on May 6, 2015.
Additional Information about the Transaction
In connection with the proposed transaction, the Company will furnish a proxy statement with the U.S. Securities and Exchange Commission (“SEC”). INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and shareholders may obtain a free copy of the proxy statement (when available) and other documents filed by ClickSoftware at the SEC’s website at http://www.sec.gov. The proxy statement (when available) and other relevant documents may also be available for download on ClickSoftware’s Investors section on its website http://ir.clicksoftware.com, or obtained for free from ClickSoftware by directing a request to Investor Relations, ClickSoftware Technologies Ltd., 94 Em-Hamoshavot Road, PO Box 3697, Petach Tikva, Israel 49527, telephone: +972-3-7659-467.
About ClickSoftware
ClickSoftware (NasdaqGS: CKSW) is the leading provider of automated mobile workforce management and service optimization solutions for the enterprise, both for mobile and in-house resources. As pioneers of the “Service chain optimization” and “The real-time service enterprise” concepts, our solutions provide organizations with end-to-end visibility and control of the entire service management chain by optimizing forecasting, planning, shift and task scheduling, mobility and real-time management of resource and customer communication.
Available via the cloud or on-premise, our products incorporate best business practices and advanced decision-making algorithms to manage service operations more efficiently, in a scalable, integrated manner. Our solutions have become the backbone for many leading organizations worldwide by addressing the fundamental question of job fulfillment: Who does What, for Whom, With what, Where and When.
ClickSoftware is the premier choice for delivering superb business performance to service sector organizations of all sizes. The Company is headquartered in the United States and Israel, with offices across Europe, and Asia Pacific. For more information, please visit http://www.clicksoftware.com. Follow us on Twitter, the content of which is not incorporated herein by reference.
To download ClickSoftware’s investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, the content of which is not incorporated herein by reference, please visit Apple’s App Store to download on your iPhone and iPad, or Google Play for your Android mobile device.
About Francisco Partners
Francisco Partners is a leading global private equity firm, which specializes in investments in technology and technology-enabled services businesses. Since its launch over 15 years ago, Francisco Partners has raised approximately $10 billion in capital and invested in more than 150 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in transaction values ranging from $50 million to over $2 billion, where the firm’s deep sectorial knowledge and operational expertise can help companies realize their full potential.
Safe Harbor for Forward Looking Statements
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to, those statements regarding the potential acquisition of the Company by Francisco Partners, including statements regarding the long-term investments, growth and other benefits, as well as the expected timing of the proposed merger. And the Company’s expectations for revenues and net operating loss for the first quarter of 2015. Such “forward-looking statements” involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. Achievement of these results by ClickSoftware may be affected by many factors, including, but not limited to, risks and uncertainties regarding the ability to close the proposed transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the approval by the Company’s shareholders; the risk that the benefits of the potential transaction may not be fully realized or may take longer to realize than expected; the impact of the proposed transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions, and completion of the Company’s normal quarter-end accounting process and review for the first quarter of 2015 by the Company’s independent and registered public accounting firm. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in ClickSoftware’s annual report on Form 20-F for the year ended December 31, 2014 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, ClickSoftware is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
ClickSoftware Contact: | Investor Relations Contact: |
Noa Schuman | Christopher Harrison |
Investor Relations | KCSA Strategic Communications |
+972-3-7659-467 | 212-896-1267 |
Noa.Schuman@clicksoftware.com | charrison@kcsa.com |
(LTRX) xPrintServer Mobile Printing Solution Selected By Global Technology Provider
Easy-to-Use, Enterprise-Ready xPrintServer – Office Edition Extends Ricoh Copier and Print Systems Capabilities to Apple Mobile Devices
IRVINE, CA–(Apr 29, 2015) – Lantronix, Inc. (NASDAQ: LTRX), a specialized networking company providing smart IoT and M2M solutions, announced that its xPrintServer® – Office Edition mobile printing solution has been added to Ricoh’s line of network accessories. Ricoh will resell the xPrintServer to provide its customers with a mobile solution that enables quick and easy wireless printing for iPads®, iPhones® and other iOS-enabled Apple devices.
The Lantronix xPrintServer – Office Edition is a “plug-and-print” solution that will allow customers to print directly from iOS devices to their Ricoh printer, or virtually any printer, without installing special software or applications. By simply plugging in the xPrintServer anywhere on the Local Area Network, it will auto-discover the printers on the network. The Office Edition offers several security and enterprise management features, including remote authentication, active directory management and proxy server support.
With more and more companies seeking a mobile solution as part of the RFQ process, the time was now for Ricoh to add to its line of network accessories. “The faster employees are able to move information from their mobile device to a printer, the faster they can complete projects, share information and collaborate,” said Jason Dizzine, Director, Product Marketing, Ricoh Americas Corporation. “This improved workflow enhances information mobility, and we are excited to now offer the Lantronix xPrintServer – Office Edition as a solution to help meet the mobile printing demands of our customers in the new world of work.”
The xPrintServer wireless capabilities don’t end with iOS devices. In just a few steps, IT personnel can also set up Mac desktops and Windows PCs. The xPrintServer solution complements Ricoh’s line of existing network accessories that provide the flexibility to simply and easily move beyond the limitations of network cables and connect output devices wherever and however is desirable.
“Ricoh is a global leader in information mobility for today’s changing workforce, with a strong legacy of introducing new technologies into the workplace and a deep expertise in managing and accessing information,” said Kurt Busch, president and CEO of Lantronix. “We are pleased that our xPrintServer has been selected by Ricoh to provide their customers with a seamless mobile printing solution that will allow them to leverage the expanding population of smart devices in today’s work environments. Ricoh’s selection of the xPrintServer is an example of one of the ways Lantronix is engaging with Tier One accounts to expand sales opportunities for our Enterprise Solutions products across many different verticals.”
About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a specialized networking company providing M2M (machine to machine) and IoT (Internet of Things) solutions. Our products deliver secure connectivity, device management and mobility for today’s increasingly connected world. By networking and managing devices and machines that have never before been connected, we enable our customers to realize the possibilities of the Internet of Things. Founded in 1989, Lantronix pioneers robust, intelligent and easy to deploy solutions for mission critical applications in a wide range of industries, including data center, medical, security, industrial, transportation, retail, financial and government. Lantronix is headquartered in Irvine, California, with offices in Europe, Asia and Japan. For more information, visit www.lantronix.com.
Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.
© 2015 Lantronix, Inc. Lantronix and xPrintServer are registered trademarks of Lantronix, Inc. in the United States and certain other countries. All other trademarks and trade names are the property of their respective holders. Specifications subject to change without notice. All rights reserved.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2812235
Media Contacts:
Stephanie Olsen
Lages & Associates, Inc.
stephanie@lages.com
949.453.8080
Rosie Anderson
TOUCHDOWNPR
randerson@touchdownpr.com
+44 1252 717040
Investor Contact:
E.E. Wang
investors@lantronix.com
949-614-5879
Lantronix Contact:
Mark D. Tullio
Lantronix
mark.tullio@lantronix.com
949.453.7124
(EPIQ) Names Jill Bauer as Managing Director
Industry Veteran Appointment Further Strengthens Senior Bankruptcy Management Team
KANSAS CITY, Kan., April 29, 2015 — Epiq Systems, Inc. (Nasdaq:EPIQ), a leading global provider of integrated technology solutions for the legal profession, today announced the appointment of Jill Bauer as managing director of Chapter 7 Bankruptcy Solutions & Fiduciary Services.
In this newly created role, Ms. Bauer will drive strategic positioning and brand awareness of Epiq within the Chapter 7 trustee community and ensure continued delivery of Epiq’s highly effective and streamlined approach to case administration. Additionally, Ms. Bauer will lead the group in bringing to market fiduciary services offerings.
Ms. Bauer brings twenty-five years of business development and management experience within the bankruptcy industry and fiduciary markets. She served 10 years at Bankruptcy Management Solutions, Inc. (BMS) as senior vice president where she led Chapter 7 sales and services and implemented Chapter 11 software and service offerings. Prior to BMS, she served 13 years at JP Morgan Chase as senior vice president in the Chase Technology Solutions Group. Most recently, Ms. Bauer served as a senior officer in East West Bank’s specialty deposits services group.
“With Jill’s appointment, we add an accomplished bankruptcy and business development expert at the helm of our market-leading Chapter 7 solutions business,” said Brad D. Scott, president and chief operating officer, Epiq Systems. “Jill’s expertise in product development and client support greatly enhances our capabilities to serve our clients’ needs in this area. Her experience and proven leadership track record are an added strength for the firm.”
About Epiq Systems
Epiq Systems is a leading global provider of integrated technology solutions for the legal profession, including electronic discovery, bankruptcy, and class action and mass tort administration. We also offer full-service capabilities to support litigation, investigations, financial transactions, regulatory compliance and other legal matters. Our innovative technology and services, deep subject-matter expertise and global presence spanning 45 countries served from more than 20 locations allow us to provide secure, reliable solutions to the worldwide legal community. Visit us at www.epiqsystems.com.
CONTACT: Investor Contacts Kelly Bailey Epiq Systems 913-621-9500 ir@epiqsystems.com Chris Eddy or David Collins Catalyst Global 212-924-9800 epiq@catalyst-ir.com
(MDVX) Subsidiary Streamline(R) Prepares for New Product Introductions
Seven New Products Expected to Broaden Company’s Portfolio of Innovative Healthcare Equipment Management Solutions
ATLANTA, GA–(Apr 28, 2015) – Medovex Corporation (NASDAQ: MDVX), a developer of medical technology products, announced today that its wholly-owned subsidiary Streamline has developed and intends to commercialize seven new products building on the success of its flagship product the Streamline IV Suspension System (ISS™).
The Streamline ISS is a patient equipment management device that makes the management of patients and their equipment easy, safe and efficient within hospitals by combining the advantages of both a stand-alone and bed-mounted IV pole in one system.
The seven new expansion products are expected to serve the same target audience and call point for its already commercialized Streamline IV Suspension System. The expansion products capitalize on the existing base technology as a “suspension system” available on demand and used by the medical caregiver in the hospital setting.
Jarrett Gorlin, CEO of Medovex, stated, “As we previously announced, it was our intention with the acquisition of Streamline to pursue expansion of our product line under its current patent portfolio. Part of our goal of unlocking Streamline’s value inside of our greater scale involves the opportunity to create other products like those announced today, which leverage ISS’s patented platform.”
Gorlin continued, “We’re pleased in such short order to have developed the framework for these new products which we expect to not only complement our ISS offering, but to further our reach and market penetration within the same clinical market seeking to maximize revenue potential.”
The new products are as follows:
- Streamline® ICU Bed Table Suspension System – The bed table is an important part of patient and portable equipment support during the care of a patient in an ever increasingly complex ICU environment.
- Streamline® ICU Oxygen Tank Suspension System – Oxygen is a vital therapy source for patients. The handling and transport of patients demands effective management of small oxygen tanks in a safe and effective manner.
- Streamline® Kiddy Wagon IV Suspension System – Young children, especially those that are being treated within critical care settings need the encouraging support of mobility in a cheerful setting. The “Kiddy Wagon IV Suspension System” is expected to serve this patient population well.
- Streamline® ICU Boom Suspension System – This product will serve patients and caregivers who are cared for in the ICU where a pendent or overhead boom device is used for management of patients and their equipment.
- Streamline® ICU Combo Table Suspension System – The ICU combination device will provide multiple capabilities to serve the patient and care giver. This will allow for greater flexibility in the delivery of safe and effective care.
- Streamline® Combo Power IV Suspension System – Like the ICU Combo Table product, this product is designed to provide much needed electric power to the immediate care area of the patient when transported to another part of the hospital.
- Streamline® Wheel Chair IV Suspension System – The wheel chair is a common patient transportation vehicle in the hospital setting that requires the same attention to detail as any other patient transport.
Patrick Kullmann, President and COO, stated, “This expansion set of technology offerings will further support the needs for safe patient handling for both the patient and the health care provider. We believe the new products will provide an expanding foundation of the continuum for handling patients in a variety of care settings for both adults and pediatrics. Importantly, these new products will go directly to market without waiting for an FDA clearance, requiring a nominal capital investment while providing a quick to market opportunity.”
About Medovex:
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement:
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact
(LOGM) New Video-Aided Support Capability, Rescue Lens, TSIA Vision Finalist
BOSTON, April 29, 2015 — LogMeIn, Inc. (Nasdaq:LOGM) has been named a finalist for a 2015 Technology Services Industry Association (TSIA) Vision Award in recognition of its new Rescue Lens service. Finalist companies will demonstrate their innovations on stage in front of an audience of hundreds of services industry practitioners and a panel of experts at the Technology Services World (TSW) 2015 Best Practices conference, at the Santa Clara Convention Center, May 4-6.
Introduced in 2010, the TSIA Vision Award recognizes game-changing ideas in technology services that advance the industry and shape emerging trends. TSIA is the leading association for today’s technology services organizations.
“Simple problems can be easily overlooked when something is not working right. Rescue Lens brings remote support to virtually any product by allowing support reps to provide real-time, video-assisted aid, giving them a firsthand look at the end users problem from anywhere. This new set of capabilities improves communication with customers, speed of resolution and quality of service,” said Peter Zeinoun, Director of Products, LogMeIn Rescue. “We are honored to be recognized by TSIA and are excited to present as a finalist among the other innovators.”
Rescue Lens is a video-aided support capability aimed at addressing the rapidly expanding world of connected products – and the new needs of today’s connected customer. Using a secure, live camera feed from a customer’s or employee’s mobile device, Rescue Lens empowers customer service agents to see and remotely assist with product issues that are reported by customers, employees or other field technicians, as if the product were directly in front of them. Rescue Lens is part of LogMeIn Rescue, LogMeIn’s flagship professional remote support solution. Through Rescue Lens, customer service staff can now remotely guide these users through product setup, troubleshooting, problem resolution, and more, for virtually any connected or yet-to-be-connected product. As a result, companies can reimagine how they deliver customer service, field service, and IT support to help reduce returns, decrease costly onsite support costs, boost customer satisfaction, and even create new service offerings.
About LogMeIn, Inc.
LogMeIn, Inc. (Nasdaq:LOGM) simplifies how people connect to each other and the world around them. With millions of users worldwide, our cloud-based solutions make it possible for people and companies to connect and engage with their workplace, colleagues, customers and products anywhere, anytime. LogMeIn is headquartered in Boston with offices in Bangalore, Budapest, Dublin, London, San Francisco and Sydney.
About TSIA
The Technology Services Industry Association (TSIA) is the world’s leading organization dedicated to advancing the business of technology services. Technology services organizations large and small look to TSIA for world-class business frameworks, best practices based on real-world results, detailed performance benchmarking, exceptional peer networking opportunities, and high-profile certification and awards programs. TSIA corporate members represent the world’s top technology companies as well as scores of innovative small- and mid-size businesses in four major markets: enterprise IT and telecom, consumer technology, healthcare and healthcare IT, and industrial equipment and technology.
CONTACT: Media contact: Craig VerColen press@logmein.com
(GLUU) Announces Strategic Relationship with Tencent
Glu Mobile Inc. (Glu, NASDAQ:GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, announced that Tencent Holdings Limited (Tencent, SEHK: 00700) had agreed to purchase 21 million shares of Glu’s common stock at a price of US$6.00 per share for total consideration of US$126 million.
The transaction will be completed in two tranches, with Tencent today purchasing 12.5 million shares, and committing to purchase the remaining 8.5 million shares upon the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Subject to the foregoing, the parties expect the second tranche to be completed in Q2-2015. Tencent will own approximately 14.6% of the total shares on a fully-diluted and as converted basis immediately after completion of the investment. Glu will have a pro forma cash balance of approximately $190 million, based on Glu’s cash balance as of March 31, 2015, immediately after the completion of the transaction.
“I am proud to announce that we have entered into a strategic relationship with arguably Asia’s largest internet company and the world’s largest games company – Tencent. I consider their expertise in gaming to be unrivalled and we are excited to power ahead with the support of a fantastic partner that believes in our strategy and shares our vision,” said Niccolo de Masi, Chairman & CEO of Glu.
De Masi continued, “We are delighted to gain a new value-added Board member as part of this partnership. Steven Ma, SVP and Head of Tencent’s Interactive Entertainment Group joins our Board of Directors today. We look forward to collaborating with Tencent to bring more high quality and enjoyable gaming experience to our users.”
“Tencent was attracted to Glu due to its five-year growth track record, high-quality entrepreneurial management, and unique approach to methodically building a portfolio of success in the shooter, action-RPG, narrative-RPG, time-management, sports and racing genres,” said Steven Ma.
Mr. Ma continued, “Collaboration between our companies will enable Glu to tailor its games more powerfully by tapping Tencent’s strength in online, social and MMO capabilities. I look forward to working with Niccolo and the rest of the Glu Board to take Glu to the next level.”
Cowen and Company, LLC provided a fairness opinion to Glu’s Board of Directors in connection with this transaction.
Forward-Looking Statements
This press release contains certain “forward-looking statements” related to the business of Glu Mobile Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “plans” or similar expressions, including statements regarding the expected timing of the closing of the second tranche of Tencent’s investment in Glu; that Glu is excited to power ahead with the support of a fantastic partner that believes in our strategy and shares our vision; that Glu looks forward to collaborating with Tencent to bring more high quality and enjoyable gaming experience to Glu’s users; that collaboration between Glu and Tencent will enable Glu to tailor its games more powerfully by tapping Tencent’s strength in online, social and MMO capabilities; and that Mr. Ma looks forward to working with Mr. de Masi and the rest of the Glu Board to take Glu to the next level. Such forward-looking statements involve known and unknown risks and uncertainties, including, but not limited to, the risk that the parties do not receive antitrust clearance for the second tranche of the investment; the risk that Glu does not realize the anticipated strategic benefits from its strategic relationship with Tencent; the risk that consumer demand for smartphones, tablets and next-generation platforms does not grow as significantly as Glu anticipates or that Glu will be unable to capitalize on any such growth; the risk that Glu does not realize a sufficient return on its investment with respect to its efforts to develop free-to-play games for smartphones, tablets and next-generation platforms; the risk that Glu will not be able to maintain its good relationships with Apple and Google; the risk that Glu’s newly released games will be of a quality less than desired by reviewers and consumers; the risk that the mobile games market, particularly with respect to free-to-play gaming, is smaller than anticipated; the risk that Glu may lose a key intellectual property license; and other risks detailed under the caption “Risk Factors” in Glu’s Form 10-K filed with the Securities and Exchange Commission on March 13, 2015 and Glu’s other SEC filings. You can locate these reports through Glu’s website at http://www.glu.com/investors. We are under no obligation, and expressly disclaim any obligation, to update or alter these forward-looking statements whether as a result of new information, future events or otherwise.
About Glu Mobile
Glu Mobile (NASDAQ:GLUU) is a leading global developer and publisher of free-to-play games for smartphone and tablet devices. Glu is focused on creating compelling original IP games such as CONTRACT KILLER, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, and TAP SPORTS BASEBALL, and branded IP games including KIM KARDASHIAN: HOLLYWOOD, ROBOCOP: THE OFFICIAL GAME, and HERCULES: THE OFFICIAL GAME, on the App Store, Google Play, Amazon Appstore, Facebook, Mac App Store, and Windows Phone. Glu’s unique technology platform enables its titles to be accessible to a broad audience of consumers globally. Founded in 2001, Glu is headquartered in San Francisco with major U.S. offices outside of Seattle and in Long Beach, and international locations in Canada, China, India, Japan, Korea, and Russia. Consumers can find high-quality entertainment wherever they see the ‘g’ character logo or at www.glu.com. For live updates, please follow Glu via Twitter at www.twitter.com/glumobile or become a Glu fan at Facebook.com/glumobile.
BLOOD & GLORY, CONTRACT KILLER, DEER HUNTER, DINER DASH, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, TAP SPORTS BASEBALL, GLU, GLU MOBILE and the ‘g’ character logo are trademarks of Glu Mobile Inc. or its subsidiaries.
ICR, Inc.
Seth Potter, 646-277-1230
ir@glu.com
(USAT) & Chase Form Strategic Relationship
USA Technologies, Inc. (NASDAQ: USAT), a leader of wireless, cashless payment and M2M/IoT solutions for small-ticket, self-serve retailing industries and Chase Commerce Solutions, the global payment processing, merchant acquiring and offers business of JPMorgan Chase & Co., today announced a new strategic relationship. Through a multi-year agreement, self-service retailers can benefit from USAT’s best-in-class cashless payments and M2M/IoT service with the added strength, security and expanded reach of Chase Commerce Solutions’ market-leading payment processing.
“There is an evolution happening in the way that both consumers and merchants handle money and it begins with mobile and cashless payment technology,” stated Dave DeMedio, chief financial officer of USA Technologies. “We have helped thousands of small-ticket self-serve retail merchants to seamlessly make a transition to cashless payments, and there is still much growth opportunity in the space. This strategic relationship represents the first step with Chase Commerce Solutions toward expanding our footprint through leveraging inherent economies of scale.”
With payment options such as credit card, debit card and mobile payment options available to consumers, USAT’s portfolio of cashless payment, telemetry and consumer engagement services help self-serve retail businesses’ transition to cashless acceptance easy and frictionless.
The companies believe that this strategic relationship brings greater opportunities for USAT to scale more rapidly, and to expand its product lines into new domestic and global verticals and markets, while providing Chase Commerce Solutions inroads into the self-service retail markets. USAT estimates the market size at more than $120 billion in annual transaction volumes, and 13-15 million potential “merchant locations” in the U.S.
“We continue to enable commerce through a simple, secure payment experience for consumers and for our business clients,” said Kimberly Fitzsimmons, U.S. Market President for Chase Commerce Solutions. “We are pleased to work with USA Technologies, a market leader in this important and rapidly emerging space to accept all types of payments easily and securely.”
About USA Technologies, Inc.:
USA Technologies is a leader of wireless, cashless payment and M2M/IoT telemetry solutions for small-ticket, self-serve retailing industries. ePort Connect® is the company’s flagship service platform, a PCI-compliant, end-to-end suite of cashless payment and telemetry services specially tailored to fit the needs of small ticket, self-service retailing industries. USA Technologies also provides a broad line of cashless acceptance technologies including its NFC-ready ePort® G-series, ePort Mobile™ for customers on the go, and QuickConnect, an API Web service for developers. USA Technologies has been granted 87 patents; and has agreements with Verizon, Visa, MasterCard, and customers such as Compass and others. Visit the website at www.usatech.com.
About Chase Commerce Solutions:
Chase Commerce Solutions is the global payment processing, merchant acquiring and offers business of JPMorgan Chase & Co. The business is comprised of Chase Paymentech, its global merchant acquiring business, Chase Pay, its proprietary online digital wallet and ChaseNet, its customized closed-loop proprietary payments platform. Commerce Solutions is a leading provider of payment, fraud and data security for companies large and small and capable of authorizing transactions in more than 130 currencies. The business enables integrated solutions for all payment types, including credit, debit, prepaid stored value and electronic check processing; as well as alternative and mobile. In 2014, Commerce Solutions processed 38.1 billion transactions with a value of $847.9 billion, and in March 2015, was ranked as the No. 1 wholly owned U.S. Merchant Acquirer by The Nilson Report.
Forward-looking Statements:
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: All statements, other than statements of historical fact included in this release, are forward-looking statements. When used in this release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions, as they relate to USAT or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of USAT’s management, as well as assumptions made by and information currently available to USAT’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, business, financial, market and economic conditions; the ability of USAT to predict future or any market conditions and consumer behavior; the extent to which the Chase contract would help USAT to increase scale and broaden its mobile payments footprint; and the possibility that all of the expected benefits from better data and market offerings will not be realized by all of our customers, or will not be realized to the extent predicted and/or within the expected time period. Readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement made by us in this release speaks only as of the date of this release. Unless required by law, USAT does not undertake to release publicly any revisions to these forward-looking statements to reflect future events or circumstances or to reflect the occurrence of unanticipated events.
USA Technologies:
ANW Networks
Melissa Hourigan, +1 720-872-8807
melissa@anwnetworks.com
or
ANW Networks
Emily F. Porro, +1 347-960-3603
emily@anwnetworks.com
or
Investor Relations:
BlueShirt Group
Michael Bishop, +1 415-217-4968
mike@blueshirtgroup.com
or
Chase Commerce Solutions:
Edward Kozmor, +1 302-282-7170
edward.kozmor@chase.com
(MCUR) to Participate in Upcoming ARVO Annual Meeting
PETACH TIKVA, Israel, April 28, 2015 — Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that it will participate in the upcoming Annual Meeting of The Association for Research in Vision & Ophthalmology (ARVO) from May 3 – 7, 2015 in Denver, Colorado.
2015 ARVO Annual Meeting
Website: http://www.arvo.org/Annual_Meeting/
Abstract:
- Title: GROWTH FACTOR CHARACTERIZATION OF LIVING HUMAN ACTIVATED LEUKOCYTE SUSPENSION (LHALS) AND EFFECT ON PRIMARY HUMAN CORNEAL EPITHELIAL CELL PROLIFERATION
- Program Number: 709
- Poster Board Number: C0257
- Author(s): Shah, Vivek1, Naumenko, Pavel1 , Zuloff-Shani, Adi1, Li, William2, Molyneaux, Michael1, 1Research & Development Macrocure, Ltd., Tenafly, NJ, United States; 2The Angiogenesis Foundation, Cambridge, MA, United States
- Date: Sunday, May 3, 2015
- Time: 1:30-3:15 PM
- Presenter: Vivek Shah, PhD
- Venue: Colorado Convention Center; Exhibit Hall Poster Session
About Macrocure Ltd.
Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company’s novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body’s own wound healing and regenerative components directly into the wound itself.
About CureXcell
Macrocure’s lead product candidate, CureXcell, is a unique combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. CureXcell is currently in two pivotal, Phase III, double-blind clinical trials targeting a broad indication for the treatment of all types of wounds below the knee. For more information, please visit: www.macrocure.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market, including those risks discussed under the heading “Risk Factors” in Macrocure’s Annual Report on Form 20-F for the year ended December 31, 2014 filed with the Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this announcement and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476; francesca@macrocure.com
(DXR) Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer
NEW YORK, NY–(Apr 28, 2015) – Daxor Corporation, (NYSE MKT: DXR) a medical instrumentation and biotechnology company, announced the receipt of a signed contract from Lankenau Medical Center of Wynnewood, Pennsylvania, for the placement of a BVA-100 Blood Volume Analyzer. Lankenau Medical Center is a 331 bed tertiary care, teaching hospital and research institute
Lankenau Medical Center serves southeastern Pennsylvania by offering a wide variety of primary and specialty clinical services, residency and fellowship programs, research programs emphasizing cardiovascular disease, cancer and diabetes. Their Emergency Department is certified by the Joint Commission as a Primary Stroke Center. An FAA certified rooftop helipad is available for medevacs.
Lankenau Medical Center is a founding member of Main Line Health, which is a community-based not-for-profit health system that also includes Bryn Mawr Hospital, Paoli Hospital, Riddle Hospital, Bryn Mawr Rehabilitation Hospital, and Mirmont Treatment Center.
Dr. Christopher Droogan, Medical Director of Heart Failure at Lankenau Medical Center, was quoted as saying the following regarding the upcoming placement of the BVA-100 Blood Volume Analyzer:
“In an effort to effectively diagnose proper volume status in many of our critically ill medical and surgical patients as well as the varied heart failure population in our hospital, we look forward to using the Daxor Blood Volume Analyzer to assist our clinicians in their daily practice of medicine. We hope to eliminate unnecessary blood transfusions and decrease invasive hemodynamic monitors which carry risk. In an effort to reduce early readmission we hope to better appreciate the under-treated acutely decompensated heart failure patient.”
Dr. Joseph Feldschuh, a cardiologist and the CEO of Daxor, said: “As patients become more aware of how essential blood volume measurement is, they will better understand the importance of being treated on the basis of direct measurement rather than estimates based on imprecise measures.”
The Daxor website provides important additional information to help patients understand the benefit of blood volume measurement and which medical facilities in various states across the country are able to provide this life saving test.
To learn more about Daxor, please visit www.Daxor.com.
Contact Information:
Daxor Corporation:
Richard Dunn
212-330-8502
(Director of Operations)
rdunn@daxor.com
David Frankel
212-330-8504
(Chief Financial Officer)
dfrankel@daxor.com
Diane Meegan
212-330-8512
(Investor Relations)
dmeegan@daxor.com
(SREV) Appoints Joe Kovach as Chief Transformation Officer
ServiceSource® (NASDAQ:SREV), the global leader in recurring revenue growth and customer success management, today appointed professional services and technology leader, Joe Kovach, as the company’s new Chief Transformation Officer, effective May 15. Kovach, who will oversee ServiceSource’s Corporate IT and Technical Operations teams, brings 30 years of industry experience and expertise including sales, service delivery, account management, business development and executive management to the role. Kovach will be responsible for transforming ServiceSource’s use of cutting-edge technology and best-practice processes to deliver Revenue Lifecycle Management (RLM) solutions that provide extremely high levels of customer satisfaction, efficiency and effectiveness.
“This role represents an important step forward in ServiceSource’s future, helping us provide continually higher levels of customer-centric RLM solutions to the market,” said Christopher Carrington, CEO of ServiceSource. “With Joe on our team, our world-class services and solutions teams will have an incredible new partner in helping accelerate the use of technology to deliver world-class technology and best-practice processes.”
Prior to joining ServiceSource, Kovach worked with Capgemini as the senior vice president for Americas. Before that, he served as senior vice president of the ATOS Systems Integration Practice in North America, where he significantly grew the practice through helping his clients apply leading-edge technology and process improvement to their business challenges. In previous roles, Kovach has served as the CIO of R.L. Polk and Company and Advanced Energy Industries, leading successful transformation efforts at both companies. He has also been vice president of professional services at Siemens IT Solutions and Services, and vice president of C&I Worldwide at Hewlett-Packard.
“Across my career, my goal has always been to help companies to grow and maintain prosperous customer relationships through the optimal use of leading technology and expert professional services, which aligns perfectly with ServiceSource’s mission,” said Kovach. “I’m very excited by the tremendous opportunity around Revenue Lifecycle Management, and am looking forward to helping ServiceSource deliver best-in-class revenue growth and customer success solutions to our clients.”
About ServiceSource
ServiceSource (NASDAQ:SREV) provides the world’s leading B2B companies with expert managed services, best-practice processes, and cloud software proven to increase customer success, drive revenue growth and decrease churn from existing customers. ServiceSource’s solutions help companies with onboarding and adoption, upsell and cross-sell, retention and renewals—across the entire revenue lifecycle. Only ServiceSource brings to market more than 15 years of exclusive focus on customer success and revenue growth, global deployments across 40 languages and 150 countries, and a powerful, purpose-built recurring revenue technology platform. Thanks to ServiceSource, another customer is renewed every 47 seconds. For more information, go to www.servicesource.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the prospects for ServiceSource’s business and offerings. These forward-looking statements are based on our current assumptions and beliefs, and involve risks and uncertainties that could cause our results to differ materially from those expressed or implied in our forward-looking statements. Those risks and uncertainties include, without limitation, fluctuations in our quarterly results of operations; the risk of material defects or errors in our software offerings or their failure to meet customer expectations; migrating customers to our SaaS offerings and the ability to integrate such offerings with other third-party applications used by our customers; errors in estimates as to the renewal rate improvements and/or service revenue we can generate for our customers; our ability to grow the market for service revenue management; our ability to protect our intellectual property rights; the risk of claims that our offerings infringe the intellectual property rights of others; changes in market conditions that impact our ability to sell our SaaS solutions and/or generate service revenue on our customers’ behalf; the possibility that our estimates of service revenue opportunity under management and other metrics may prove inaccurate; demand for our offering that falls short of expectations; our ability to keep customer data and other confidential information secure; our ability to adapt our solution to changes in the market or new competition; general political, economic and market conditions and events; and other risks and uncertainties described more fully in our periodic reports and registration statements filed with the Securities and Exchange Commission, which can be obtained online at the Commission’s website at http://www.sec.gov. All forward-looking statements in this press release are based on information currently available to us, and we assume no obligation to update these forward-looking statements.
Connect with ServiceSource:
http://www.facebook.com/ServiceSource
http://twitter.com/servicesource
http://www.linkedin.com/company/servicesource
http://www.youtube.com/user/ServiceSourceMKTG
Trademarks
ServiceSource, Renew OnDemand, Scout and any ServiceSource product or service names or logos above are trademarks of ServiceSource International, Inc. All other trademarks used herein belong to their respective owners.
ServiceSource
Crishel Bonfante, 415-901-5919
cbonfante@servicesource.com
or
Barokas PR for ServiceSource
Monica Petraitis, 206-264-8220
servicesource@barokas.com
(NURO) Launch Progress of Quell Wearable Pain Relief w/ iOS App
NeuroMetrix, Inc. (Nasdaq: NURO) reported today the Quell™ app is now available in the Apple app store. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for people with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia and pain associated with osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription.
The app enhances Quell by providing the user with a real-time therapy dashboard, therapy and sleep tracking over weeks and months, the ability to customize their Quell device, and instructional videos. Quell communicates with mobile devices running the app through Bluetooth® Smart.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit www.QuellRelief.com and www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
(INVT) Issued New Patent for Data Transmission Enhancement
Company Expands Telecommunications Coverage, Adding US Patent to Its Intellectual Property (IP) Portfolios
CAMPBELL, CA–(Apr 28, 2015) – Intellectual property licensing company Inventergy Global, Inc. (NASDAQ: INVT) has strengthened its presence in the global telecommunications industry with its newly-issued patent, US Patent Number 9,015,546 (4/21/2015), adding to the patented inventions granted to the Company since acquiring substantial telecommunications portfolios from Nokia, Panasonic and Huawei.
The newly issued ‘546 patent is titled “AUTOMATIC RETRANSMISSION REQUEST CONTROL SYSTEM AND RETRANSMISSION METHOD IN MIMO-OFDM SYSTEM,” and the covered technology helps improve data throughput performance. As an example, an invention described in the ‘546 patent enhances data throughput performance in various telecommunications systems by improving accuracy in the retransmission of signals and reducing the number of retransmission requests.
Joe Beyers, CEO of Inventergy, said, “The technology covered by the ‘546 patent provides further valuable advances in data throughput performance, a key for telecommunication service providers delivering ever-better service to their customers.”
He added, “Inventergy has developed processes to establish, maintain, and expand upon its IP portfolio. The addition of high quality, technologically relevant patents increases the value of the Company and its assets.”
About Inventergy Global, Inc.
Inventergy Global, Inc. is a Silicon Valley-based intellectual property company dedicated to identifying, acquiring and licensing the patented technologies of market-significant technology leaders. Led by IP industry pioneer and veteran Joe Beyers, former head of IP and global strategy at Hewlett-Packard, the Company leverages decades of experience, market and technology expertise, and industry connections to assist Fortune 500 companies in leveraging the value of their innovations to achieve greater returns. Inventergy aspires to enable a new world of IP value creation built upon a more transparent, above-board and ethical business platform. Inventergy’s current portfolio now contains approximately 760 patent assets (including patents related to industry standards), from three Fortune Global 500 and Gartner-recognized technology leaders in the telecommunications industry. For more information about Inventergy, visit the website at www.inventergy.com.
Forward-Looking Statements
This press release contains statements, estimates, forecasts and projections with respect to future performance and events, which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent and belief or current expectations of the Company and its affiliates and subsidiaries and their respective management teams. These statements may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek” and similar expressions and include any projections or estimates set forth herein. Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, that actual results may differ materially from those projected in the forward-looking statements.
Investors:
Andrew Haag
Managing Partner, Investor Relations
IRTH Communications
Office: 866.976.4784
invt@irthcommunications.com
(AMCO) China to Adjust Export Tariffs of 94 Commodities
SAN MATEO, Calif., April 27, 2015 — Armco Metals Holdings, Inc. (“Armco Metals Holdings”) (NYSE MKT:AMCO), a distributor of imported metal ores and a steel recycler in China, today announced that its subsidiaries will possibly benefit from the recent export tariff changes by China government, which export tariffs of 94 commodities closely related with the iron and steel industry will be adjusted starting from May 2015, according to the announcement from the Ministry of Finance of China on April 23, 2015. Iron and steel granules and powders, tungsten, and molybdenum will be exempt from export tariffs, and wrought aluminum products will have a zero tax rate. Export tariffs on 90 commodities in the list will be eliminated and the other four commodities will receive a tax reduction. Export tariffs before the adjustment range up to 25% depending upon the commodity.
During 2014, in response to the excess production capacity in the industry and constantly declining price of iron ore, we significantly reduced our import-based trading business by 57% as compared to 2013, and increased our trading business of exporting metal products. We believe that the elimination and reduction on the export tariff for the commodities may provide us with additional opportunities to grow our trading business.
The iron and steel industry in China are confronted with excess production capacity for several years and squeeze on bank lending, the elimination and reduction on the export tariff for the commodities would relieve the stress on the whole industry undoubtedly and ease the shortage of our working capital in especial besides the trading opportunities bring about. We would take advantage of the favorable policies and work for a turn to better.
ABOUT ARMCO METALS HOLDINGS, INC.
Armco Metals Holdings, Inc. is engaged in the sale and distribution of metal ore and non-ferrous metals throughout China and is in the recycling business in China. Armco Metals’ customers include some of the fastest growing steel producing mills and foundries throughout China. Raw materials are acquired from a global group of suppliers located in various countries, including, but not limited to, Brazil, India, Indonesia, Ukraine and the United States. Armco Metals’ product lines include ferrous and non-ferrous ore, iron ore, chrome ore, nickel ore, magnesium, copper ore, manganese ore, steel billet and recycled scrap metals. For more information about Armco Metals, please visit http://www.armcometals.com.
SAFE HARBOR STATEMENT
In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Armco Metals Holdings, Inc., is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) are forward-looking and involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding our revenues and production related to our scrap metal recycling operations, pricing and demand for our product lines and the extent of government imposed energy and monetary policy restrictions and resulting blackouts and associated impact on our trading and recycling operations.
We caution that investors should not place undue reliance on any forward-looking statements herein. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. This press release is qualified in its entirety by the following, including, but not limited to, any expectations with respect to the Company’s revenues and operations, institution of governmental regulations relating to our businesses and the international economic climate, and the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filing with the Securities and Exchange Commission.
CONTACT: Armco Metals Holdings, Inc. US Investor Relations Contact Christina Xiong Office: 650.212.7620 Email: ir@armcometals.com Website: www.armcometals.com China Ripple Zhang Office: 86-21-62375286 Email: ripple.zhang@armcometals.com Website: www.armcometals.com
(CNIT) Agreement to Establish Regional Cloud Computing Center in Mianyang City
SHENZHEN, China, April 27, 2015 — China Information Technology, Inc. (the “Company” or “CNIT”) (Nasdaq GS: CNIT), a leading provider of integrated cloud-based platform, exchange, and big data solutions in China, today announced that the Company has entered into a strategic agreement with the Youxian Economic Development Zone to establish the Company’s regional cloud-computing center in Mianyang City of Sichuan Province.
According to the agreement, the Company will leverage its proprietary “Cloud-App-Terminal” (CAT) model and “Cloud Nest” data analytics to provide cloud-computing services for customers in Mianyang and other cities of Sichuan Province. It is expected that CNIT’s cloud-computing solutions will help local companies better manage data, understand customer needs and improve user experience.
“We are pleased to collaborate with the Mianyang municipal government in establishing our regional cloud-computing center in Southwest China,” said Mr. Jiang Huai Lin, Chairman and CEO of the Company. “Mianyang is a key research and manufacturing hub for the electronics industry in Western China. After laying down the infrastructure, our growth strategy is to roll out our cloud-based new media services in various fields starting with beauty salons and to penetrate the Southwestern China region over time.”
“Mianyang is a national pilot city for the information technology industry, and we welcome CNIT,” said Lei Zheng, Vice Mayor of Mianyang City. “The municipal government gives full support to help CNIT quickly setup their cloud-computing operation. CNIT is an industry leader in cloud-based new media solutions. We believe this strategic cooperation will contribute to the growth of the information technology industry of our City, and will build Mianyang as a model of digital Smart City in Southwestern China.”
As the only “Science and Technology City” named by the State Council, Mianyang is a key research and manufacturing center for the defense and electronics industries in China. Mianyang enjoys the reputation as the “Silicon Valley in Western China” and “Smart City”. Mianyang was selected by the State Council among the first group of national pilot cities for promoting the integration of finance and technologies as well as among the first group of national pilot cities to adopt a single data cable servicing Internet, telephone and television.
About China Information Technology, Inc.
China Information Technology, Inc. (CNIT) is on a mission to make advertising accessible and affordable for businesses of all sizes. CNIT is a leading Internet service company that provides cloud-based platform, exchange, and big data solutions enabling innovation and smart living in the education, health care, new media, finance and transportation sectors. Through continuous innovation, CNIT is leveraging its proprietary Cloud-Application-Terminal technology to level the competitive landscape in the new media industry and deliver value for its shareholders, employees, customers, and the community. To learn more, please visit http://www.chinacnit.com.
Safe Harbor Statement
This press release may contain certain “forward-looking statements” relating to the business of China Information Technology, Inc., and its subsidiaries and other consolidated entities. All statements, other than statements of historical fact included herein, are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, often identified by the use of forward-looking terminologies such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company and its subsidiaries and other consolidated entities or persons acting on their behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For further information, please contact:
China Information Technology, Inc.
Tiffany Pan
Tel: +86-755-8370-4767
Email: ir@chinacnit.com
Grayling
Shiwei Yin
Investor Relations
Tel: +1.646.284.9474
Email: cnit@grayling.com
(CHEK) Receives Notice of U.S. Patent Allowance For Endoscopy Technology
ISFIYA, Israel, April 27, 2015 — Check-Cap Ltd., (Nasdaq: CHEK, CHEKW) a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application U.S. 13/825,018 entitled, “Estimation of Distances and Size of Lesions in the Colon with an Imaging Capsule.” The patent broadly covers Check-Cap’s investigational preparation-free endoscopy capsule with a colon imaging system for detecting colorectal cancer and clinically-significant pre-cancerous polyps, and outlines a method for measuring distances inside a patient’s colon and optionally using the measurements to construct an image of the inside of the colon. Once granted, the patent is expected to be valid through 2031.
The Check-Cap imaging system consists of an ingestible capsule that transmits colon section measurements through a radio frequency (RF) link to a data recorder. The single-use, disposable capsule is approximately 34 millimeters long and 11.5 millimeters wide, making it similar in size to other capsule endoscopy products. It advances through the body by natural motility, painlessly capturing and continuously transmitting data reflecting the colon’s internal surface with the help of a contrast agent before being excreted naturally within two to three days. Patients are able to continue their normal daily routines throughout the process including normal food intake. Upon test completion, gastroenterologists or radiologists can analyze the data from any computer in less than 10 minutes.
The Check-Cap imaging system requires no fasting or prior bowel cleansing as the imaging capsule employs X-rays for colon section measurements. The X-rays are ultra-low dose (with radiation exposure approximating that of a single chest X-ray) and allow for 3-dimensional imaging of the lining of the colon even when the capsule is surrounded by intestinal content. The ability to transmit a full 360-degree radius around the capsule is expected to allow for the detection of polyps including those located behind colon folds.
“We are encouraged to receive this Notice of Allowance for another patent that will extend intellectual property coverage of our proprietary endoscopy capsule technology in the United States, representing a significant milestone and protecting the significant R&D work we have done,” said Guy Neev, chief executive officer, Check-Cap. “Although colon cancer can be classified as preventable or curable with the aid of early screening, many patients have been reluctant to undergo currently available procedures. We are encouraged by the early clinical evidence suggesting the ability to image the preparation-free human colon and are optimistic that the Check-Cap imaging system may be an acceptable option for millions of patients.”
In late 2015, Check-Cap plans to file for a CE mark for the marketing and sale of the Company’s endoscopy capsule in the European Union and expects to perform post-marketing studies in Europe following CE marking for the purpose of collecting additional clinical data to support market adoption. Check-Cap anticipates initiating a clinical trial for FDA approval during 2016.
More than one million new cases of colorectal cancer are reported each year worldwide, according to the World Cancer Research Fund International. The World Health Organization attributes 690,000 deaths annually to this cancer, which is the second leading cause of cancer-related deaths in the western world. Invasive colonoscopy, considered the gold standard for colorectal screening, requires thorough cleansing of the colon, which many patients find to be the most burdensome aspect of colon cancer screening.
About Check-Cap Ltd.
Check-Cap is a clinical stage medical diagnostics company focused on the development of gastrointestinal imaging devices. The Company’s lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and clinically-significant pre-cancerous polyps that utilizes proprietary, ultra-low-energy X-ray-based measurement technology to safely generate high-resolution, 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. This solution is designed to increase compliance with screening recommendations. The Check-Cap imaging system is not cleared for marketing in any jurisdiction.
Legal Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the “Special Note On Forward-looking Statements” and “Risk Factors” in the Company’s Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACT:
Investors
David Carey
Lazar Partners Ltd.
212-867-1768
dcarey@lazarpartners.com
(AEHR) Receives $6 Million Order for a FOX-15(TM)
FREMONT, Calif., April 27, 2015 — Aehr Test Systems (Nasdaq:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced it has received an order from a new customer for a FOX-15 Multi-Wafer Test and Burn-In System, multiple WaferPak™ contactors and a WaferPak Aligner. The order is for more than $6 million and is for a production test and burn-in application. The order includes prepayments in order to lock in lead times and volume-related discounts and is expected to ship within the next six months.
“We are very excited to announce our initial order from this major new customer,” said Gayn Erickson, President and CEO of Aehr Test Systems. “This production customer is extremely quality and cost conscious, which makes them a great match for the reliability and yield improvements that our wafer level burn-in and test solutions provide.”
“We see the markets for automotive sensors and infotainment, mobile consumer electronic devices, servers with high-reliability stacked flash memory, and ultimately the Internet of Things (IoT), as key growth opportunities for Aehr Test’s wafer level test and burn-in solutions,” said Carl Buck, Aehr Test Vice President of Marketing. “Aehr Test currently has an installed base of customers using our FOX-15 multi-wafer test systems in the automotive sensor and data communications spaces with systems configured to test and burn-in 15 wafers in parallel in high volume production today. This new customer’s production application represents a significant opportunity for Aehr Test as we expand our unique and highly cost effective wafer level test and burn-in solution into the rapidly growing automotive, consumer, mobile, and computing markets.”
Buck continued, “Extensive test and burn-in is required to weed out early-life failures to meet the standards of automotive and quality conscious consumer, server, and mobile device manufacturers. The challenge is how to handle these devices, which are often extremely small, measuring in the one to few millimeters in size and having thousands or even tens of thousands of devices per wafer. Contacting the devices in package form is often both impractical and expensive. Aehr Test provides a unique solution to contact and test all of the devices at once in wafer form. Today, we test wafers with up to 20,000 devices at a time and can do this at elevated temperatures up to 170C with our proprietary WaferPak contactors. Typical packaged part burn-in systems can only go to 150C and typical wafer probe cards used in production today may only go up to 125C. Aehr Test can make contact with the very small contact pads that are often under 100 microns wide (less than four one-thousandths of an inch) and 200 microns apart from each other versus typical pads on surface mount package parts with 300 microns wide pads that are 1,000 microns apart. Our customers have shown that handling and burning-in their devices in wafer form is much more reliable and leads to higher quality and lower defect rates in the end products. Our FOX-15 multi-wafer burn-in system can burn-in 15 wafers at once, allowing customers to test thousands of devices on each of the 15 wafers in parallel, providing them with a very low cost platform for doing test and burn-in of their wafers.”
Aehr Test’s FOX family of products is focused on high reliability test needs and long-duration full wafer burn-in and test of products such as sensors, automotive ICs, discrete memories, and devices with embedded memories including microcontrollers and smart card devices. The FOX-1 system offers high-throughput single-touchdown sort testing. The FOX-15 system has a capacity of up to 15 WaferPak single-touchdown full wafer contactors for burn-in and test of state-of-the-art integrated circuits and sensors. Testing the ICs in wafer form before they are assembled into multi-die stacked packages enables the stacked packages to then be used for high reliability and quality applications such as enterprise solid state drives, automotive devices, mission critical integrated circuits and sensors. Aehr Test’s recently-introduced FOX-1P system extends the capabilities of its FOX-1 system by adding high density, low cost I/O and DPS modules with the capability to provide over 16,000 I/O or DPS channels in a single test head for massive parallelism on a single wafer.
About Aehr Test Systems
Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic and memory integrated circuits and has an installed base of more than 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, capacity needs and opportunities for Aehr Test products in package and wafer level test. Aehr Test has developed and introduced several innovative products, including the ABTSTM and FOX families of test and burn-in systems and the DiePak® carrier. The ABTS system is used in production and qualification testing of packaged parts for both low-power and high-power logic as well as all common types of memory devices. The FOX system is a full wafer contact test and burn-in system used for burn-in and functional test of complex devices, such as leading-edge memories, digital signal processors, microprocessors, microcontrollers and systems-on-a-chip. The DiePak carrier is a reusable, temporary package that enables IC manufacturers to perform cost-effective final test and burn-in of bare die. For more information, please visit Aehr Test’s website at www.aehr.com.
Safe Harbor Statement
This press release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. These statements are based on information available to Aehr Test as of the date hereof and actual results could differ materially from those stated or implied due to risks and uncertainties. Forward-looking statements include statements regarding Aehr Test’s expectations, beliefs, intentions or strategies regarding the FOX products, including statements regarding future market opportunities and conditions, expected product shipment dates and customer orders or commitments. These risks and uncertainties include, without limitation, acceptance by customers of the FOX and WaferPak contactor technologies, acceptance by customers of the FOX system, WaferPak Aligner and WaferPak contactors shipped upon receipt of a purchase order and the ability of new products to meet customer needs or perform as described, as well as general market conditions, customer demand and acceptance of Aehr Test’s products and Aehr Test’s ability to execute on its business strategy. See Aehr Test’s recent 10-K, 10-Q and other reports from time to time filed with the Securities and Exchange Commission for a more detailed description of the risks facing Aehr Test’s business. Aehr Test disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.
CONTACT: Aehr Test Systems Carl Buck V.P. of Marketing (510) 623-9400 x381 cbuck@aehr.com MKR Group Inc. Todd Kehrli or Jim Byers Analyst/Investor Contact (323) 468-2300 aehr@mkr-group.com
(INCR) Files Registration Statement for Secondary Offering
RALEIGH, N.C., April 27, 2015 — INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, today announced that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed secondary offering of up to 9,200,000 shares (which includes 1,200,000 shares subject to the underwriters’ option to purchase additional shares) of its Class A common stock by certain of its existing stockholders, including affiliates of Avista Capital Partners, L.P.; affiliates of Teachers’ Private Capital, the private investment arm of Ontario Teachers’ Pension Plan Board; and certain current and former employees of INC Research. INC Research will not receive any of the proceeds from the sale of the shares.
In addition, INC Research intends to enter into an agreement with certain selling stockholders to repurchase an aggregate of $150.0 million of common stock from certain selling stockholders in a private transaction, concurrently with the closing of the offering, at the price at which the shares of common stock are sold to the public in the offering, less underwriting discounts and commissions. The closing of the share repurchase is contingent on, and expected to occur simultaneously with, the closing of the offering, subject to the satisfaction of other customary conditions. The closing of the offering is not contingent on the closing of the share repurchase.
Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC will act as the lead book-running managers for the offering. Jefferies LLC will act as a book-running manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The registration statement INC Research has filed with the SEC can be obtained by visiting EDGAR on the SEC website at www.sec.gov.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, email: prospectus-ny@ny.email.gs.com, Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: newyork.prospectus@credit-suisse.com, or Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: 877-547-6340, email: Prospectus_Department@Jefferies.com.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries.
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks regarding whether we can complete the offering and regarding its impact on the trading price of our Class A common stock; potential volatility; risks associated with our business and our debt; and the other risk factors set forth from time to time in our Form S-1 and other SEC filings, copies of which are available free of charge on our website at www.incresearch.com. INC Research assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: Investor.Relations@incresearch.com Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 345-1685 Email: Corporate.Communications@incresearch.com
(CANF) Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial
Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis; Company prepares protocol of next advanced psoriasis trial
PETACH TIKVA, Israel, April 27, 2015 — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.
The study included 326 patients through 17 clinical centers in the U.S., Europe, and Israel with a duration of 32 weeks where the primary endpoint was after 12 weeks. On March 30, 2015, Can-Fite announced the study did not meet its primary endpoint of a statistically significant improvement in the Psoriasis Area Severity Index (PASI) 75 score relative to placebo after 12 weeks of treatment. However, based on further analysis of the efficacy and safety results from the study as described below, Can-Fite intends to continue the development of CF101 for the treatment of psoriasis and has initiated work on the design of the next advanced–stage clinical trial protocol.
Further analysis of the entire study period revealed that by 32 weeks of treatment with CF101, 33% of the patients achieved PASI 75 while the mean percent of improvement in PASI score was 57% (p<0.001) . This was a statistically significant cumulative and linear improvement during weeks 16 to 32.
Most significantly, by week 32 of the study, 20% of the study patients reached PASI 90, a result demonstrating a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to meet clinical endpoints for measuring responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher and significant (p=0.026) CF101 response rate of 27% among patients previously untreated with systemic psoriasis therapy compared to patients pre-treated with systemic drugs. The Company believes this presents the opportunity that CF101 can be developed as a first-line systemic therapy for patients with moderate-severe psoriasis and for patients who do not want to be treated with the current systemic drugs due to safety issues. Currently there is no universally accepted first-line systemic therapy for patients diagnosed with psoriasis, and therefore CF101, an orally bioavailable drug with an excellent safety profile can be positioned for this unmet need.
“The cumulative and linear improvement in CF101’s efficacy treating moderate to severe psoriasis over a longer period of time is a very significant finding for Can-Fite and the psoriasis treatment market. Based on the very favorable safety data on CF101 from this and other trials, coupled with its oral administration, we believe CF101 offers a valuable potential treatment solution for psoriasis and we are committed to continuing our development program,” stated Can-Fite CEO Dr. Pnina Fishman. “We are particularly encouraged by the new data that show CF101 could serve as a first-line therapy for moderate-severe psoriasis based on the higher efficacy in patients who were previously not treated with systemic therapy.”
About Psoriasis
Psoriasis is a skin condition that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic biologic drugs, delivered via IV, have dominated the market. According to the National Psoriasis Foundation, common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders, and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable.
About CF101
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. CF101 is currently developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (completed Phase II) and psoriasis (Phase II/III).
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s CF101 recently completed its Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is in Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. The Company’s CF602 has shown efficacy in the treatment of erectile dysfunction. Can-Fite has initiated a full pre-clinical program for CF602 in preparation for filing an IND with the U.S. FDA in this indication. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
(UBIC) Presents at Bio-IT World Conference and Expo
Highlighting the Results of a Test to Extract Semantic Relationships among Healthcare-Related Words
NEW YORK, April 24, 2015 — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) (“UBIC” or “the Company”), a leading provider of international litigation support and big-data analysis services, participated in the Bio-IT World Conference & Expo 2015, which was held in Boston on April 21-23.
Jakob Halskov, Ph.D., Senior Technical Researcher at UBIC’s Behavior Informatics Laboratories, presented a poster session titled “Extracting Biomedical Knowledge from Text Using Knowledge Patterns” and reported on the results of a test to extract biomedical knowledge from textual information. This test aimed at enhancing knowledge related to healthcare by extracting semantic relationships among healthcare-related words from large amounts of unstructured data (free descriptive text data) available on the Internet. A similar, previous test was successfully conducted with regard to English text data, and the latest test examined the applicability of this method to Chinese texts. By harnessing these test results, it may be possible to identify (1) side-effects that may occur resulting from the use of a certain drug and (2) drugs that may have caused certain symptoms. Believing that the knowledge gained through the test will be applicable to the fields of drug discovery and drug safety, the Behavior Informatics Laboratories continues to conduct research in this field.
The Bio-IT World Conference & Expo attracts more than 3,000 researchers in such fields as life sciences, drug discovery, clinical medicine and IT, as well as a number of companies in the IT, biomedical and drug discovery sectors. As a forum for exchange among people from industry, government and academia, Bio-IT World has been held annually since 2002. For detailed information on Bio-IT World Conference & Expo 2015, please access the website of the organizer at: http://www.bio-itworldexpo.com/.
UBIC intends to apply its proprietary technologies cultivated in the field of litigation support to other fields, including healthcare. UBIC will continue to contribute to social development by providing high-quality services that make use of behavior informatics technology.
About UBIC, Inc.
UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) supports the analysis of big data based on behavior informatics by utilizing its proprietary AI-based software program, “VIRTUAL DATA SCIENTIST” or VDS. Developed by UBIC based on knowledge acquired through its litigation support services, the VDS program incorporates experts’ tacit knowledge, including their experiences and intuitions, and utilizes that knowledge for big data analysis. UBIC continues to expand its business operations by applying VDS to new fields such as healthcare and marketing.
UBIC was founded in 2003 as a provider of e-discovery and international litigation support services. These services include the preservation, investigation and analysis of evidence materials contained in electronic data, and computer forensic investigation. UBIC provides e-discovery and litigation support by making full use of its data analysis platform, “Lit i View®”, and its Predictive Coding technology adapted to Asian languages.
For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubicna.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.
CONTACT: UBIC Global PR UBIC North America, Inc. Tel: (212) 924-8242 global_pr@ubic.co.jp
(CTSO) Issues Letter to Shareholders
MONMOUTH JUNCTION, N.J., April 24, 2015 — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients, issued a letter to its shareholders as part of its annual report, from its Chief Executive Officer, Dr. Phillip Chan, which reads as follows:
Dear Fellow Shareholders and Friends,
By all measures, 2014 was an outstanding year for CytoSorbents, highlighted by many significant achievements. We exceeded our internal forecasts for CytoSorb® sales growth, fueled by broadening physician interest and usage in a growing number of countries. We established or strengthened key strategic partnerships with Fresenius Medical Care, Biocon, and a major global cardiac surgery company, and expanded distribution of CytoSorb® to 29 countries worldwide. These initiatives have the potential to catalyze significant future growth. We also began the clinical trial process needed to bring CytoSorb® home to the U.S., initially for the application of cardiac surgery, and possibly later for other applications. Finally, with the support of our shareholders, we became a NASDAQ-listed company, giving CytoSorbents much broader visibility in the investment community and significantly increasing liquidity for shareholders.
With that said, the most exciting part of this journey has been the growing number of stories of how CytoSorb® has helped, in some way, save the lives of ordinary people like you and me. These patients find themselves in the intensive care unit because of common life-threatening conditions such as sepsis and infection, lung injury, trauma, burn injury, pancreatitis, liver failure, and many others where inflammation plays a potentially deadly role. Left untreated, severe uncontrolled inflammation can lead to multiple organ failure, where patients spiral out of control and become unresponsive to therapy, leaving families and physicians with the difficult prospect of having to potentially withdraw life-support. The fact that CytoSorb® therapy has been used to reduce the “fuel to the fire” of this inflammation and help bring many of these people back from the brink of death is, to me as a physician, nothing short of remarkable.
To be clear, the diseases we treat are some of the most complex life-threatening conditions in medicine for which no effective therapies exist, and where the risk of death is still one in every three patients despite the best medical treatment. We have no expectation that CytoSorb® will work every time. But with the collaboration and experience of a growing number of physicians who have collectively performed more than 5,500 human treatments to date, we have made significant progress toward identifying which diseases and patients best respond to CytoSorb® therapy. Centralized data from our recently launched International CytoSorb® Registry and from the more than 50 planned investigator-initiated and company-sponsored studies (a dozen of which are already enrolling patients), will also be invaluable to understanding the full potential of CytoSorb®. We now have the funding and clinical development team to advance our trial agenda more aggressively, particularly in the areas of sepsis and cardiac surgery – our two largest markets.
A significant new opportunity has emerged that may accelerate U.S. approval of CytoSorb® for critical illnesses such as sepsis. The FDA has recently issued new guidance on two related topics: the Expedited Access Pathway (EAP) program and the Balancing of Pre-market and Post-market Data Collection for Devices Subject to Premarket Approval. Together, the EAP and Data Collection programs are designed to facilitate and expedite the U.S. approval of medical devices that treat life-threatening or irreversibly debilitating conditions that have no approved alternative treatments. Similar to “Breakthrough Therapy Designation” for drugs and biologics, devices that achieve EAP Designation would be eligible for more intensive FDA guidance and collaboration with senior managers, and priority review. Meanwhile, the FDA and Device Sponsor would work together to specify the clinical trial design and “least burdensome” efficacy and safety data needed for early marketing approval, leaving the proof of more stringent efficacy to the post-market period. The end result is that devices that are safe and achieve EAP Designation have an opportunity to get to U.S. approval and commercialization much faster, and with less regulatory risk. We believe this new program could benefit CytoSorbents as CytoSorb® currently targets the treatment of many life-threatening conditions such as sepsis, acute respiratory distress syndrome, severe acute pancreatitis, trauma, and many others that do not have effective treatments. As we move forward with our REFRESH cardiac surgery trial in the U.S., we plan to aggressively pursue this EAP opportunity for critical care applications in parallel, and foster open collaboration with the FDA.
We have started 2015 in the strongest financial and commercial position in our history, well-capitalized with a healthy cash position, no debt, and the highest international awareness and interest in our CytoSorb® therapy that we have ever seen. Although we face some potential challenges such as the weakness in the Euro, the need to strengthen our direct sales force, and the unpredictability of timely country-specific product registrations, we continue to believe that the many potential opportunities for significant future growth greatly outweigh these near-term concerns. As detailed in our April 7, 2015 press release responding to Frequently Asked Questions, we have a clear strategy and plan on how to drive long-term, sustainable growth of our business.
Before I conclude, I should comment on the potential use of CytoSorb® as a rescue therapy for “cytokine release syndrome”, or CRS, that can lead to cytokine storm in activated T-cell immunotherapy cancer treatments. This is one of the most promising and exciting areas of cancer research where a patient’s own white blood cells (T-cells) are engineered to recognize and kill cancer cells. This is a strategy being pursued by major corporate and university alliances such as Novartis/University of Pennsylvania, Juno Therapeutics/Memorial Sloan Kettering/Fred Hutchinson Cancer Center/Seattle Children’s Research Institute, Celgene/Bluebird Bio, Kite Pharma/National Cancer Institute, GlaxoSmithKline/Adaptimmune, Merck KGaA/Intrexon/MD Anderson, and Pfizer/Cellectis. In a number of studies, the use of activated T-cells has led to the “cure” or remission of many refractory leukemias and other cancers. Common to all of these activated T-cell therapies is the potent stimulation of the inflammatory response, leading to an expected extended “flu-like” syndrome in patients, characterized by high levels of cytokines. However, CRS can spiral out of control, despite the use of tocilizumab and other prophylactic measures, leading rapidly to multiple organ failure and often death. CRS is exactly what CytoSorb® was designed to control and we believe that CytoSorb® represents a potentially unique rescue therapy to treat immune overstimulation in T-cell immunotherapy. While we are still in the beginning phases of exploring this new opportunity, CytoSorbents already has several initiatives underway.
After a fantastic 2014, we are tremendously excited about the opportunities this year and beyond. We are deeply grateful for the continued faith and effort of our extended CytoSorbents family: our patients and their families, the physicians and nurses on the front lines using our therapy, our shareholders, advisors, Board of Directors, distributors, strategic partners, research collaborators, and importantly, our more than 50 dedicated employees and consultants both here and in Berlin, Germany. Together, we can help revolutionize the treatment of deadly inflammation, and help give patients a fighting chance.
Finally, we fondly remember Joseph Rubin (1938-2014), our co-founder and Board Director, whose unwavering faith in the potential of our CytoSorb® technology to help people remains an inspiration to us all.
Sincerely,
Dr. Phillip Chan, MD, PhD
Chief Executive Officer
CytoSorbents Corporation
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation — with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company’s flagship product, is approved in the European Union with distribution established in 29 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s website: http://www.cytosorbents.com/.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(NVEE) Announces Date for 2015 Annual Meeting of Stockholders
HOLLYWOOD, FL–(Apr 24, 2015) – NV5 Holdings, Inc. (the “Company” or “NV5”) (NASDAQ: NVEE), a provider of professional and technical engineering and consulting solutions, announced today that its 2015 annual meeting of stockholders will occur on June 6, 2015. The annual meeting will be held at 9:00 a.m., local time, at the Monte Carlo Resort and Casino, 3770 Las Vegas Blvd. South, Las Vegas, Nevada. The record date for determination of stockholders entitled to vote at the annual meeting is April 15, 2015.
About NV5
NV5 Holdings, Inc. (NASDAQ: NVEE) is a provider of professional and technical engineering and consulting solutions to public and private sector clients in the infrastructure, energy, construction, real estate and environmental markets. NV5 primarily focuses on five business verticals: construction quality assurance, infrastructure, engineering and support services, energy, program management, and environmental solutions. The Company operates 36 offices in California, Colorado, Florida, Massachusetts, New Jersey, Ohio, Pennsylvania, Utah and Wyoming and is headquartered in Hollywood, Florida. For additional information, please visit the Company’s website at www.NV5.com. Also visit the Company on Twitter, LinkedIn, Facebook, and Vimeo.
Contact
NV5 Holdings, Inc.
Lauren Wright, Ph.D.
Director of Investor Relations
Tel: +1-408-392-7233
Email: ir@nv5.com
(CJJD) Announces Change in Auditing Firm
HANGZHOU, China, April 10, 2015 — China Jo-Jo Drugstores, Inc. (“China Jo-Jo”, or the “Company”) (NASDAQ CM: CJJD), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, today announced that it has engaged BDO China Shu Lun Pan Certificated Public Accountants LLP (“BDO China”) as the Company’s new independent auditing firm effective on April 7, 2015. The appointment of BDO China was approved by the Company’s Audit Committee.
BDO is one of the leading global accounting firms with member firms in over 144 countries. BDO China was founded in 1927 and is one of the earliest and most influential accounting firms in China. BDO China’s clients include over 300 listed companies, over 300 IPO companies, and more than 2,000 enterprises with foreign investments. The companies BDO provides services to cover a wide range of sizes and industries including large national enterprises, state-owned companies, commercial banks, securities companies, futures brokerage, insurance, trusts and funds.
With BDO China team’s large local presence and its well-established reputation, the Company believes that BDO China is well qualified to become its independent auditing firm. The Company does not believe that the change of auditor will affect the timely filing of its annual report on Form 10-K for the year ending March 31, 2015.
For more information on the Company’s change in auditing firm, please refer to the Company’s Form 8-K filed on April 7, 2015:
http://www.sec.gov/Archives/edgar/data/1413263/000121390015002561/f8k040715_chinajojo.htm
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of December 31, 2014, the Company had 60 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).
Forward Looking Statement
Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “estimate,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.
(INNL) Announces Pricing of Follow-On Offering
ATHLONE, Ireland, April 24, 2015 — Innocoll AG (Nasdaq:INNL), a specialty pharmaceutical company, today announced the pricing of its follow-on public offering of 3,321,669 American Depositary Shares (“ADSs”) at a public offering price of $9.00 per ADS. Of the ADSs in the offering, 1,999,690 ADSs are being offered by the Company and 1,321,979 ADSs are being offered by selling shareholders. The Company will not receive any proceeds from the sale of ADSs by the selling shareholders. The offering is expected to close on April 30, 2015, subject to the satisfaction of customary closing conditions.
The Company expects to receive total estimated net proceeds from this offering of approximately $16.1 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes and the development of its products.
Piper Jaffray & Co. is acting as sole manager for the offering. The offering of these securities is being made only by means of a prospectus, copies of which can be obtained from: Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 23, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The Company’s late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company’s approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma.
CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the Company.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not of historical facts may be deemed to be forward-looking statements. You can identify these forward-looking statements by words such as ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”intends,” ”may,” ”could,” ”might,” ”will,” ”should,” ”aims,” or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the industry in which we operate and the trends that may affect the industry or us, as well as the timing of the closing of the public offering or our ability to complete the public offering on the anticipated terms or at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption “Risk Factors” in the Company’s Registration Statement on Form F-1 and in other reports the Company files with the U.S. Securities and Exchange Commission, including its Annual Report of Foreign Issuer on Form 20-F. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.
CONTACT: Corporate: Denise Carter Executive Vice President Business Development and Corporate Affairs T: (215) 765-0149 E: dcarter@innocollinc.com Investor relations: Robert Flamm, Ph.D. Senior Vice President Russo Partners, LLC. T: (212) 845-4226 E: Robert.flamm@russopartnersllc.com
(CHLN) Announces 1-for-5 Reverse Stock Split Effective April 24, 2015
XI’AN, China, April 24, 2015 — China Housing & Land Development, Inc. (“China Housing” or the “Company”) (Nasdaq: CHLN) today announced that it has filed a Certificate of Change pursuant to Nevada Revised Statutes (“NRS”) Section 78.209 with the Secretary of State of Nevada to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the proportional decrease of the Company’s authorized shares of Common Stock at a ratio of one-for-five (1-for-5) (the “Reverse Split”). The Reverse Split was authorized by the Board of Directors of the Company pursuant to Section 78.207 of the NRS on April 3, 2015 and, pursuant to the Certificate of Change, became effective as of April 24, 2015. The Company’s Common Stock will continue to trade under the symbol “CHLN” but under a new CUSIP number: 16939V202.
Following the Reverse Split, each stockholder’s percentage ownership in the Company and the proportional voting power remains unchanged, with the exception of minor changes and adjustments resulting from rounding up of fractional interests. No fractional shares of the Company’s Common Stock were issued in connection with the Reverse Split, and any stockholders entitled to receive a fractional post-split share received one (1) whole post-split share.
The Company implemented the Reverse Split to regain compliance with NASDAQ continued listing standards. Following the Reverse Split the Company has approximately seven (7) million shares of Common Stock issued and outstanding. In addition, the total number of authorized shares of Common Stock was proportionately reduced from 100 million to 20 million shares.
For further information regarding the Reverse Split, please refer to the Company’s Form 8-K to be filed with the Securities and Exchange Commission (the “Commission”) and available on the Commission’s website at www.sec.gov following the effectiveness of the Reverse Split.
About China Housing & Land Development, Inc.
Based in Xi’an, the capital city of China’s Shaanxi province, China Housing is a developer of residential and commercial properties in northwest China. China Housing has been engaged in land acquisition, development, and management, including the sales of residential and commercial real estate properties through its wholly owned subsidiary in China, since 1992.
China Housing is the first Chinese real estate development company traded on NASDAQ. The Company’s news releases, project information, photographs, and more are available on the Internet at www.chldinc.com.
Safe Harbor
This news release may contain forward-looking information about China Housing which is covered under the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as believe, expect, may, will, should, project, plan, seek, intend, or anticipate or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and China Housing’s future performance, operations, and products.
Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual performance results may vary significantly from expectations and projections. Further information regarding this and other risk factors are contained in China Housing’s public filings with the Commission.
All information provided in this news release and in any attachments is as of the date of the release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
China Housing contacts
Ms. Jing Lu
Chief Operating Officer, Board Secretary, Director and Investor Relations Officer
+86 29 8258 2639
jinglu@chldinc.com
Mr. Bill Zima, ICR
+86 10 6583 7511
William.Zima@icrinc.com
China Housing Investor Relations Department
+1 646 308 1285
(UNXL) Sets Operational Update Call for Monday, April 27 at 4:30 p.m. ET
THE WOODLANDS, TX–(Apr 23, 2015) – UniPixel, Inc. (NASDAQ: UNXL), a provider of Performance Engineered Films™ to the touch screen, flexible printed electronics and display markets, will hold a conference call on Monday, April 27, 2015 at 4:30 p.m. Eastern time to discuss the recent acquisition of the assets and operations of Atmel Corporation’s XSense® touch sensors group and the company’s outlook.
UniPixel management will host the presentation, followed by a question and answer period.
The call will be webcast live here, as well as via a link in the Investors section of the company’s website at www.unipixel.com/investors. Webcast participants will be able to submit a question to management via the webcast player.
Date: Monday, April 27, 2015
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Webcast: http://public.viavid.com/index.php?id=114304
To participate in the conference call via telephone, dial 1-913-312-0699 and provide the conference name or conference ID 8200263. Please call the conference telephone number 10 minutes prior to the start time so the operator can register your name and organization.
If you have any difficulty with the webcast or connecting to the call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available after 7:30 p.m. Eastern time on the same day through May 27, 2015, via the same link above, or by dialing 1-858-384-5517 and entering replay ID 8200263.
About XSense Touch Sensors
XSense™ touch sensors enable new design possibilities for touch-enabled products. Based on proprietary roll-to-roll metal mesh technology, XSense touch sensors support features such as narrow borders, curved touch surfaces and even edgeless touchscreens while achieving improved linearity for better Stylus performance, reliability and thinner sensor stacks. As an alternative to traditional touch sensors, XSense gives you the ability to turn your unique touch-based concepts into functional designs at lower total system costs.
About UniPixel
Headquartered in The Woodlands, Texas, UniPixel, Inc. (NASDAQ: UNXL) is developing Performance Engineered Films for the Display and Flexible Electronics markets. UniPixel’s Copperhead™ high-volume roll-to-roll or continuous flow manufacturing process offers high-fidelity replication of advanced micro-optic structures and surface characteristics over large areas. A key focus for UniPixel is developing electronic conductive films for use in electronic sensors for consumer and industrial applications. The company’s roll-to-roll electronics manufacturing process prints fine line conductive elements on thin films. The company intends to market its films for touch panel sensor, cover glass replacement, protective cover film, antenna and custom circuitry applications under the UniPixel label, and intends to eventually expand its marketing to private label or Original Equipment Manufacturers (OEM) brands. For further information, visit www.unipixel.com.
Forward-looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the companies’ respective Annual Report on Form 10-K for the year ended December 31, 2014. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the companies’ respective Annual Report on Form 10-K, quarterly reports on Form 10-Q and Current Reports on Form 8-K.
Trademarks in this release are the property of their respective owners.
Investor Relations Contact:
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
(VCYT) Announces $40 Million Private Placement
SOUTH SAN FRANCISCO, Calif., April 23, 2015 — Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under the agreement, the investors will purchase an aggregate of 4,907,975 shares of common stock at a purchase price of $8.15 per share, the closing stock price on April 22, 2015. The private placement was led by new and existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners and venBio, among others.
The private placement is expected to close on or about April 27, 2015, subject to the satisfaction of customary closing conditions. Veracyte intends to use the net proceeds from the placement to fund research and development, for product commercialization, and for working capital and general corporate purposes. Veracyte had $25.8 million in cash at March 31, 2015.
Piper Jaffray & Co. acted as sole lead placement agent and William Blair & Company, L.L.C. acted as a co-placement agent for the transaction.
The securities to be sold in the private placement have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from such registration requirements. Veracyte has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock sold in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 15,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. The Afirma test is recommended in leading practice guidelines and is covered for 145 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods and include, among others, statements we make regarding the anticipated gross proceeds from the transaction, the expected closing date of the transaction, the expected use of proceeds from the transaction, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks related to whether Veracyte will be able to satisfy the conditions required to close the sale of the shares in the private placement and the fact that Veracyte’s management will have broad discretion in the use of the proceeds from any sale of the shares; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.
Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.
Media:
Tracy Morris
650-380-4413
tracy.morris@veracyte.com
Investors:
Pam Lord
Canale Communications
619-849-6003
pam@canalecomm.com
TraderPower Featured Companies
Top Small Cap Market News
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
Recent Posts
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
Recent Comments
Archives
- October 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009